Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update

Trevi Therapeutics, Inc. (NASDAQ:TRVI) was the recipient of a significant drop in short interest in November. As of November 30th, there was short interest totalling 1,410,000 shares, a drop of 19.4% from the November 15th total of 1,750,000 shares. Based on an average daily volume of 511,500 shares, the short-interest ratio is currently 2.8 days.

Analysts Set New Price Targets

TRVI has been the subject of several recent analyst reports. Leerink Partnrs raised shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a research note on Thursday. Raymond James initiated coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They set an “outperform” rating and a $9.00 price objective for the company. D. Boral Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research note on Thursday. Finally, B. Riley reaffirmed a “buy” rating and set a $6.00 price objective on shares of Trevi Therapeutics in a research note on Monday, October 7th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $9.31.

Trevi Therapeutics Trading Up 4.1 %

Shares of TRVI traded up $0.17 during mid-day trading on Monday, reaching $4.34. The company’s stock had a trading volume of 2,074,557 shares, compared to its average volume of 598,443. The stock has a market cap of $333.62 million, a PE ratio of -10.20 and a beta of 0.96. Trevi Therapeutics has a 52 week low of $1.26 and a 52 week high of $4.60. The company’s fifty day moving average price is $2.99 and its two-hundred day moving average price is $2.93.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same period in the previous year, the company posted ($0.08) EPS. Research analysts anticipate that Trevi Therapeutics will post -0.49 EPS for the current year.

Institutional Investors Weigh In On Trevi Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its holdings in Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after buying an additional 6,764 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Trevi Therapeutics during the 1st quarter valued at $47,000. Intech Investment Management LLC bought a new stake in Trevi Therapeutics during the 3rd quarter valued at $63,000. Hsbc Holdings PLC bought a new stake in Trevi Therapeutics during the 2nd quarter valued at $61,000. Finally, SG Americas Securities LLC bought a new stake in Trevi Therapeutics during the 3rd quarter valued at $78,000. 95.76% of the stock is currently owned by institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.